跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
程 毅君
教授
,
麻醉學科
合聘教授
,
生物科技高階管理碩士在職專班
主治醫師
,
衛生福利部雙和醫院
https://orcid.org/0000-0002-0201-4380
電子郵件
stainless1019
gmail
com
h-index
1574
引文
23
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1993 …
2025
每年研究成果
概覽
指紋
網路
專案
(13)
研究成果
(114)
資料集
(2)
類似的個人檔案
(12)
指紋
查看啟用 Yih-Giun Cherng 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Odds Ratio
100%
Cohort Analysis
87%
Apoplexy
65%
Retrospective Cohort Study
63%
Hazard Ratio
55%
Adverse Outcome
47%
General Anesthesia
36%
Major Surgery
35%
Randomized Controlled Trial
33%
Liver Cirrhosis
26%
Neuraxial Anesthesia
24%
Propensity Score Matching
24%
Chronic Kidney Disease
23%
Noncardiac Surgery
23%
Spinal Anaesthesia
23%
Osteoblast
23%
End Stage Renal Disease
23%
Hospital Mortality
22%
Adverse Event
21%
Logistic Regression Analysis
20%
Dry Eye
20%
Postoperative Complication
19%
Intensive Care Unit
18%
Eye Disease
18%
Parkinson's Disease
17%
Fatty Acid Desaturation
17%
Nephropathy
17%
Hepatocellular Carcinoma
17%
Meta-Analysis
17%
Estrogen Receptor Alpha
17%
Maturation
17%
Morphine
17%
Diabetes
17%
Postoperative Nausea and Vomiting
16%
Septicemia
15%
Intravenous Patient-Controlled Analgesia
14%
Sevoflurane
14%
Surgery
13%
Observational Study
12%
Analgesia
12%
Ocular Surface
11%
Geriatrics
11%
Cesarean Section
11%
Sex Difference
11%
Dental Scaling
11%
Lymphocyte
11%
Influenza Vaccination
11%
Genistein
11%
Nasal Cannula
11%
Heart Surgery
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
78%
Estrogen Receptor Alpha
23%
Postoperative Nausea and Vomiting
23%
Adverse Outcome
21%
Randomized Controlled Trial
21%
Adverse Event
20%
Mouse
20%
Diabetes Mellitus
18%
Genistein
17%
Chronic Kidney Failure
17%
Lipopolysaccharide
17%
Parkinson's Disease
17%
Propofol
15%
Hospital Mortality
15%
Dry Eye
14%
Caspase
12%
Eye Disease
11%
End Stage Renal Disease
11%
Mitogen Activated Protein Kinase
11%
Liver Cell Carcinoma
11%
Morphine
11%
Neostigmine
11%
Desflurane
11%
Levobupivacaine
11%
Estrogen Receptor
11%
Glioblastoma
11%
Urinary Tract Infection
11%
Adenosine Triphosphate
10%
Sevoflurane
9%
Acute Heart Infarction
8%
Alkaline Phosphatase
8%
Septicemia
8%
Malignant Neoplasm
8%
Reactive Oxygen Metabolite
8%
Antiemetic Agent
8%
Nitric Oxide
7%
Carcinogenesis
7%
Phosphotransferase
7%
Osteocalcin
7%
Peroxisome Proliferator Activated Receptor
7%
Inflammation
7%
Duragesic
7%
Protein Kinase C
7%
Injury
6%
Bone Defect
6%
Nitroprusside Sodium
6%
Nausea and Vomiting
6%
Bupivacaine
6%
Streptozotocin
6%
Gastrointestinal Hemorrhage
6%
Nursing and Health Professions
Confidence Interval
55%
Odds Ratio
54%
Cohort Analysis
50%
Adverse Outcome
33%
Propensity Score
27%
Hazard Ratio
20%
Liver Cirrhosis
18%
National Health Insurance
17%
Adverse Event
15%
Major Surgery
11%
Parkinson's Disease
11%
Systematic Review
11%
Septicemia
10%
Postoperative Nausea and Vomiting
10%
Hospital Mortality
10%
Urinary Tract Infection
9%
Logistic Regression Analysis
8%
Acute Heart Infarction
7%
Gastrointestinal Hemorrhage
6%
Post-Anesthesia Care Unit
6%
University Hospital
6%
Intensive Care Unit
6%
Chronic Pancreatitis
5%
Gastroenteritis
5%
Pain Intensity
5%
Case-Control Study
5%
Sugammadex
5%
Kidney Disease
5%
Neostigmine
5%
Liver Surgery
5%
Alcohol Liver Disease
5%
Urologic Surgery
5%
Heart Failure
5%
Acute Pancreatitis
5%
Cigarette Filter
5%
Dental Scaling
5%
Gender Difference
5%
Morphometry
5%
Influenza Vaccination
5%
CHA2DS2-VASc Score
5%
Laryngoscopy
5%
Abdominal Surgery
5%
Hypothermia
5%
Intellectual Impairment
5%
Chronic Kidney Failure
5%
Coronary Artery Atherosclerosis
5%
Thrombocytopenia
5%
Opiate
5%
Network Meta-Analysis
5%
Peripheral Occlusive Artery Disease
5%
